fluoropyrimidine + leucovorin

Fluoropyrimidine plus leucovorin is a combination chemotherapy regimen used primarily in the treatment of gastrointestinal cancers, including colorectal cancer. The regimen typically consists of a fluoropyrimidine antimetabolite, such as **5-fluorouracil (5-FU)** or its oral prodrug **capecitabine**, administered alongside **leucovorin (folinic acid)**. Fluoropyrimidines exert their cytotoxic effect by inhibiting **thymidylate synthase (TYMS)**, an enzyme essential for DNA synthesis and repair. Leucovorin acts as a biochemical modulator that stabilizes the binding of the active metabolite of 5-FU to thymidylate synthase, thereby enhancing the inhibition of the enzyme and increasing the drug's efficacy. In the context of the **GRANITE** clinical trial (NCT05141721) sponsored by **Seattle Project Corporation** (Gritstone bio), this combination is utilized as standard-of-care maintenance therapy for patients with microsatellite stable (MSS) metastatic colorectal cancer, often in combination with bevacizumab and investigational personalized neoantigen vaccines.

Other names

5-FU + LV5-fluorouracil + leucovorincapecitabine + leucovorinfluoropyrimidine + leucovorin-Seattle Project Corporation-metastatic colorectal cancer